Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 43 entries
Sorted by: Best Match Show Resources per page
Standardized two-step testing of antibody activity in COVID-19 convalescent plasma.

iScience

Gilchuk P, Thomsen I, Yoder S, Brady E, Chappell JD, Stevens LJ, Denison MR, Sutton RE, Chen RE, VanBlargan LA, Suryadevara N, Zost SJ, Schmitz J, Pulley JM, Diamond MS, Rhoads JP, Bernard GR, Self WH, Rice TW, Wheeler AP, Crowe JE, Carnahan RH.
PMID: 34901783
iScience. 2021 Dec 08;103602. doi: 10.1016/j.isci.2021.103602. Epub 2021 Dec 08.

The COVID-19 pandemic revealed an urgent need for rapid profiling of neutralizing antibody responses and development of antibody therapeutics. The current Food and Drug Administration-approved serological tests do not measure antibody-mediated viral neutralization, and there is a need for...

Cite
Gilchuk P, Thomsen I, Yoder S, et al. Standardized two-step testing of antibody activity in COVID-19 convalescent plasma. iScience. 2021;103602doi: 10.1016/j.isci.2021.103602.
Gilchuk, P., Thomsen, I., Yoder, S., Brady, E., Chappell, J. D., Stevens, L. J., Denison, M. R., Sutton, R. E., Chen, R. E., VanBlargan, L. A., Suryadevara, N., Zost, S. J., Schmitz, J., Pulley, J. M., Diamond, M. S., Rhoads, J. P., Bernard, G. R., Self, W. H., Rice, T. W., Wheeler, A. P., Crowe, J. E., & Carnahan, R. H. (2021). Standardized two-step testing of antibody activity in COVID-19 convalescent plasma. iScience, 103602. https://doi.org/10.1016/j.isci.2021.103602
Gilchuk, Pavlo, et al. "Standardized two-step testing of antibody activity in COVID-19 convalescent plasma." iScience vol. (2021): 103602. doi: https://doi.org/10.1016/j.isci.2021.103602
Gilchuk P, Thomsen I, Yoder S, Brady E, Chappell JD, Stevens LJ, Denison MR, Sutton RE, Chen RE, VanBlargan LA, Suryadevara N, Zost SJ, Schmitz J, Pulley JM, Diamond MS, Rhoads JP, Bernard GR, Self WH, Rice TW, Wheeler AP, Crowe JE, Carnahan RH. Standardized two-step testing of antibody activity in COVID-19 convalescent plasma. iScience. 2021 Dec 08;103602. doi: 10.1016/j.isci.2021.103602. Epub 2021 Dec 08. PMID: 34901783; PMCID: PMC8653399.
Copy Download .nbib Format: NLM
Continuous HIV-1 Escape from Autologous Neutralization and Development of Cross-Reactive Antibody Responses Characterizes Slow Disease Progression of Children.

Vaccines

Dispinseri S, Cavarelli M, Tolazzi M, Plebani AM, Jansson M, Scarlatti G.
PMID: 33799407
Vaccines (Basel). 2021 Mar 14;9(3). doi: 10.3390/vaccines9030260.

The antibodies with different effector functions evoked by Human Immunodeficiency Virus type 1 (HIV-1) transmitted from mother to child, and their role in the pathogenesis of infected children remain unresolved. So, too, the kinetics and breadth of these responses...

Cite
Dispinseri S, Cavarelli M, Tolazzi M, et al. Continuous HIV-1 Escape from Autologous Neutralization and Development of Cross-Reactive Antibody Responses Characterizes Slow Disease Progression of Children. Vaccines (Basel). 2021;9(3)doi: 10.3390/vaccines9030260.
Dispinseri, S., Cavarelli, M., Tolazzi, M., Plebani, A. M., Jansson, M., & Scarlatti, G. (2021). Continuous HIV-1 Escape from Autologous Neutralization and Development of Cross-Reactive Antibody Responses Characterizes Slow Disease Progression of Children. Vaccines, 9(3), . https://doi.org/10.3390/vaccines9030260
Dispinseri, Stefania, et al. "Continuous HIV-1 Escape from Autologous Neutralization and Development of Cross-Reactive Antibody Responses Characterizes Slow Disease Progression of Children." Vaccines vol. 9,3 (2021). doi: https://doi.org/10.3390/vaccines9030260
Dispinseri S, Cavarelli M, Tolazzi M, Plebani AM, Jansson M, Scarlatti G. Continuous HIV-1 Escape from Autologous Neutralization and Development of Cross-Reactive Antibody Responses Characterizes Slow Disease Progression of Children. Vaccines (Basel). 2021 Mar 14;9(3). doi: 10.3390/vaccines9030260. PMID: 33799407; PMCID: PMC7999787.
Copy Download .nbib Format: NLM
Neutralization of Beta and Delta variant with sera of COVID-19 recovered cases and vaccinees of inactivated COVID-19 vaccine BBV152/Covaxin.

Journal of travel medicine

Yadav PD, Sapkal GN, Ella R, Sahay RR, Nyayanit DA, Patil DY, Deshpande G, Shete AM, Gupta N, Mohan VK, Abraham P, Panda S, Bhargava B.
PMID: 34230972
J Travel Med. 2021 Oct 11;28(7). doi: 10.1093/jtm/taab104.

No abstract available.

Cite
Yadav PD, Sapkal GN, Ella R, et al. Neutralization of Beta and Delta variant with sera of COVID-19 recovered cases and vaccinees of inactivated COVID-19 vaccine BBV152/Covaxin. J Travel Med. 2021;28(7)doi: 10.1093/jtm/taab104.
Yadav, P. D., Sapkal, G. N., Ella, R., Sahay, R. R., Nyayanit, D. A., Patil, D. Y., Deshpande, G., Shete, A. M., Gupta, N., Mohan, V. K., Abraham, P., Panda, S., & Bhargava, B. (2021). Neutralization of Beta and Delta variant with sera of COVID-19 recovered cases and vaccinees of inactivated COVID-19 vaccine BBV152/Covaxin. Journal of travel medicine, 28(7), . https://doi.org/10.1093/jtm/taab104
Yadav, Pragya D, et al. "Neutralization of Beta and Delta variant with sera of COVID-19 recovered cases and vaccinees of inactivated COVID-19 vaccine BBV152/Covaxin." Journal of travel medicine vol. 28,7 (2021). doi: https://doi.org/10.1093/jtm/taab104
Yadav PD, Sapkal GN, Ella R, Sahay RR, Nyayanit DA, Patil DY, Deshpande G, Shete AM, Gupta N, Mohan VK, Abraham P, Panda S, Bhargava B. Neutralization of Beta and Delta variant with sera of COVID-19 recovered cases and vaccinees of inactivated COVID-19 vaccine BBV152/Covaxin. J Travel Med. 2021 Oct 11;28(7). doi: 10.1093/jtm/taab104. PMID: 34230972; PMCID: PMC8344909.
Copy Download .nbib Format: NLM
Function is more reliable than quantity to follow up the humoral response to the Receptor Binding Domain of SARS- CoV-2 Spike protein after natural infection or COVID-19 vaccination.

medRxiv : the preprint server for health sciences

Sariol CA, Pantoja P, Serrano-Collazo C, Rosa-Arocho T, Armina A, Cruz L, Stone ET, Arana T, Climent C, Latoni G, Atehortua D, Pabon-Carrero C, Pinto AK, Brien JD, Espino AM.
PMID: 34100029
medRxiv. 2021 Aug 10; doi: 10.1101/2021.06.02.21257975.

Both the SARS-CoV-2 pandemic and emergence of variants of concern have highlighted the need for functional antibody assays to monitor the humoral response over time. Antibodies directed against the spike (S) protein of SARS-CoV-2 are an important component of...

Cite
Sariol CA, Pantoja P, Serrano-Collazo C, et al. Function is more reliable than quantity to follow up the humoral response to the Receptor Binding Domain of SARS- CoV-2 Spike protein after natural infection or COVID-19 vaccination. medRxiv. 2021;doi: 10.1101/2021.06.02.21257975.
Sariol, C. A., Pantoja, P., Serrano-Collazo, C., Rosa-Arocho, T., Armina, A., Cruz, L., Stone, E. T., Arana, T., Climent, C., Latoni, G., Atehortua, D., Pabon-Carrero, C., Pinto, A. K., Brien, J. D., & Espino, A. M. (2021). Function is more reliable than quantity to follow up the humoral response to the Receptor Binding Domain of SARS- CoV-2 Spike protein after natural infection or COVID-19 vaccination. medRxiv : the preprint server for health sciences, . https://doi.org/10.1101/2021.06.02.21257975
Sariol, Carlos A, et al. "Function is more reliable than quantity to follow up the humoral response to the Receptor Binding Domain of SARS- CoV-2 Spike protein after natural infection or COVID-19 vaccination." medRxiv : the preprint server for health sciences vol. (2021). doi: https://doi.org/10.1101/2021.06.02.21257975
Sariol CA, Pantoja P, Serrano-Collazo C, Rosa-Arocho T, Armina A, Cruz L, Stone ET, Arana T, Climent C, Latoni G, Atehortua D, Pabon-Carrero C, Pinto AK, Brien JD, Espino AM. Function is more reliable than quantity to follow up the humoral response to the Receptor Binding Domain of SARS- CoV-2 Spike protein after natural infection or COVID-19 vaccination. medRxiv. 2021 Aug 10; doi: 10.1101/2021.06.02.21257975. PMID: 34100029; PMCID: PMC8183028.
Copy Download .nbib Format: NLM
Template switching and duplications in SARS-CoV-2 genomes give rise to insertion variants that merit monitoring.

Communications biology

Garushyants SK, Rogozin IB, Koonin EV.
PMID: 34848826
Commun Biol. 2021 Nov 30;4(1):1343. doi: 10.1038/s42003-021-02858-9.

The appearance of multiple new SARS-CoV-2 variants during the COVID-19 pandemic is a matter of grave concern. Some of these variants, such as B.1.617.2, B.1.1.7, and B.1.351, manifest higher infectivity and virulence than the earlier SARS-CoV-2 variants, with potential...

Cite
Garushyants SK, Rogozin IB, Koonin EV. Template switching and duplications in SARS-CoV-2 genomes give rise to insertion variants that merit monitoring. Commun Biol. 2021;4(1):1343doi: 10.1038/s42003-021-02858-9.
Garushyants, S. K., Rogozin, I. B., & Koonin, E. V. (2021). Template switching and duplications in SARS-CoV-2 genomes give rise to insertion variants that merit monitoring. Communications biology, 4(1), 1343. https://doi.org/10.1038/s42003-021-02858-9
Garushyants, Sofya K, et al. "Template switching and duplications in SARS-CoV-2 genomes give rise to insertion variants that merit monitoring." Communications biology vol. 4,1 (2021): 1343. doi: https://doi.org/10.1038/s42003-021-02858-9
Garushyants SK, Rogozin IB, Koonin EV. Template switching and duplications in SARS-CoV-2 genomes give rise to insertion variants that merit monitoring. Commun Biol. 2021 Nov 30;4(1):1343. doi: 10.1038/s42003-021-02858-9. PMID: 34848826; PMCID: PMC8632935.
Copy Download .nbib Format: NLM
Function is more reliable than quantity to follow up the humoral response to the Receptor Binding Domain of SARS- CoV-2 Spike protein after natural infection or COVID-19 vaccination.

medRxiv : the preprint server for health sciences

Sariol CA, Pantoja P, Serrano-Collazo C, Rosa-Arocho T, Armina A, Cruz L, Stone ET, Arana T, Climent C, Latoni G, Atehortua D, Pabon-Carrero C, Pinto AK, Brien JD, Espino AM.
PMID: 34100029
medRxiv. 2021 Aug 10; doi: 10.1101/2021.06.02.21257975.

Both the SARS-CoV-2 pandemic and emergence of variants of concern have highlighted the need for functional antibody assays to monitor the humoral response over time. Antibodies directed against the spike (S) protein of SARS-CoV-2 are an important component of...

Cite
Sariol CA, Pantoja P, Serrano-Collazo C, et al. Function is more reliable than quantity to follow up the humoral response to the Receptor Binding Domain of SARS- CoV-2 Spike protein after natural infection or COVID-19 vaccination. medRxiv. 2021;doi: 10.1101/2021.06.02.21257975.
Sariol, C. A., Pantoja, P., Serrano-Collazo, C., Rosa-Arocho, T., Armina, A., Cruz, L., Stone, E. T., Arana, T., Climent, C., Latoni, G., Atehortua, D., Pabon-Carrero, C., Pinto, A. K., Brien, J. D., & Espino, A. M. (2021). Function is more reliable than quantity to follow up the humoral response to the Receptor Binding Domain of SARS- CoV-2 Spike protein after natural infection or COVID-19 vaccination. medRxiv : the preprint server for health sciences, . https://doi.org/10.1101/2021.06.02.21257975
Sariol, Carlos A, et al. "Function is more reliable than quantity to follow up the humoral response to the Receptor Binding Domain of SARS- CoV-2 Spike protein after natural infection or COVID-19 vaccination." medRxiv : the preprint server for health sciences vol. (2021). doi: https://doi.org/10.1101/2021.06.02.21257975
Sariol CA, Pantoja P, Serrano-Collazo C, Rosa-Arocho T, Armina A, Cruz L, Stone ET, Arana T, Climent C, Latoni G, Atehortua D, Pabon-Carrero C, Pinto AK, Brien JD, Espino AM. Function is more reliable than quantity to follow up the humoral response to the Receptor Binding Domain of SARS- CoV-2 Spike protein after natural infection or COVID-19 vaccination. medRxiv. 2021 Aug 10; doi: 10.1101/2021.06.02.21257975. PMID: 34100029; PMCID: PMC8183028.
Copy Download .nbib Format: NLM
Coronaviruses pandemics: Can neutralizing antibodies help?.

Life sciences

Tong PB, Lin LY, Tran TH.
PMID: 32450171
Life Sci. 2020 Aug 15;255:117836. doi: 10.1016/j.lfs.2020.117836. Epub 2020 May 22.

For the first time in Homo sapiens history, possibly, most of human activities is stopped by coronavirus disease 2019 (COVID-19). Nearly eight billion people of this world are facing a great challenge, maybe not "to be or not to...

Cite
Tong PB, Lin LY, Tran TH. Coronaviruses pandemics: Can neutralizing antibodies help?. Life Sci. 2020;255:117836doi: 10.1016/j.lfs.2020.117836.
Tong, P. B., Lin, L. Y., & Tran, T. H. (2020). Coronaviruses pandemics: Can neutralizing antibodies help?. Life sciences, 255117836. https://doi.org/10.1016/j.lfs.2020.117836
Tong, Phuoc-Bao-Viet, et al. "Coronaviruses pandemics: Can neutralizing antibodies help?." Life sciences vol. 255 (2020): 117836. doi: https://doi.org/10.1016/j.lfs.2020.117836
Tong PB, Lin LY, Tran TH. Coronaviruses pandemics: Can neutralizing antibodies help?. Life Sci. 2020 Aug 15;255:117836. doi: 10.1016/j.lfs.2020.117836. Epub 2020 May 22. PMID: 32450171; PMCID: PMC7243778.
Copy Download .nbib Format: NLM
Single-Dose Ad26.COV2.S Vaccine-Room for Improvement.

JAMA network open

Tehrani ZR, Sajadi MM.
PMID: 34726751
JAMA Netw Open. 2021 Nov 01;4(11):e2133012. doi: 10.1001/jamanetworkopen.2021.33012.

No abstract available.

Cite
Tehrani ZR, Sajadi MM. Single-Dose Ad26.COV2.S Vaccine-Room for Improvement. JAMA Netw Open. 2021;4(11):e2133012doi: 10.1001/jamanetworkopen.2021.33012.
Tehrani, Z. R., & Sajadi, M. M. (2021). Single-Dose Ad26.COV2.S Vaccine-Room for Improvement. JAMA network open, 4(11), e2133012. https://doi.org/10.1001/jamanetworkopen.2021.33012
Tehrani, Zahra Rikhtegaran, and Sajadi, Mohammad M. "Single-Dose Ad26.COV2.S Vaccine-Room for Improvement." JAMA network open vol. 4,11 (2021): e2133012. doi: https://doi.org/10.1001/jamanetworkopen.2021.33012
Tehrani ZR, Sajadi MM. Single-Dose Ad26.COV2.S Vaccine-Room for Improvement. JAMA Netw Open. 2021 Nov 01;4(11):e2133012. doi: 10.1001/jamanetworkopen.2021.33012. PMID: 34726751.
Copy Download .nbib Format: NLM
Evaluation of Protective Immunity of Peptide Vaccines Composed of a 15-mer N-terminal Matrix Protein 2 and a Helper T-Cell Epitope Derived from Influenza A Virus.

Immune network

Kim JK, Cheong S, Lee MK.
PMID: 31501717
Immune Netw. 2019 Jul 23;19(4):e29. doi: 10.4110/in.2019.19.e29. eCollection 2019 Aug.

The matrix protein 2 of influenza A virus (IFAV) has a relatively conserved ectodomain (M2e) composed of 23 amino acids, and M2e-based vaccines have been suggested to induce broad protective immunity in mice. In this study, we investigated whether...

Cite
Kim JK, Cheong S, Lee MK. Evaluation of Protective Immunity of Peptide Vaccines Composed of a 15-mer N-terminal Matrix Protein 2 and a Helper T-Cell Epitope Derived from Influenza A Virus. Immune Netw. 2019;19(4):e29doi: 10.4110/in.2019.19.e29.
Kim, J. K., Cheong, S., & Lee, M. K. (2019). Evaluation of Protective Immunity of Peptide Vaccines Composed of a 15-mer N-terminal Matrix Protein 2 and a Helper T-Cell Epitope Derived from Influenza A Virus. Immune network, 19(4), e29. https://doi.org/10.4110/in.2019.19.e29
Kim, Jeong-Ki, et al. "Evaluation of Protective Immunity of Peptide Vaccines Composed of a 15-mer N-terminal Matrix Protein 2 and a Helper T-Cell Epitope Derived from Influenza A Virus." Immune network vol. 19,4 (2019): e29. doi: https://doi.org/10.4110/in.2019.19.e29
Kim JK, Cheong S, Lee MK. Evaluation of Protective Immunity of Peptide Vaccines Composed of a 15-mer N-terminal Matrix Protein 2 and a Helper T-Cell Epitope Derived from Influenza A Virus. Immune Netw. 2019 Jul 23;19(4):e29. doi: 10.4110/in.2019.19.e29. eCollection 2019 Aug. PMID: 31501717; PMCID: PMC6722272.
Copy Download .nbib Format: NLM
Isolation of a panel of ultra-potent human antibodies neutralizing SARS-CoV-2 and viral variants of concern.

Cell discovery

Gorchakov AA, Kulemzin SV, Guselnikov SV, Baranov KO, Belovezhets TN, Mechetina LV, Volkova OY, Najakshin AM, Chikaev NA, Chikaev AN, Solodkov PP, Larichev VF, Gulyaeva MA, Markhaev AG, Kononova YV, Alekseyev AY, Shestopalov AM, Yusubalieva GM, Klypa TV, Ivanov AV, Valuev-Elliston VT, Baklaushev VP, Taranin AV.
PMID: 34667147
Cell Discov. 2021 Oct 19;7(1):96. doi: 10.1038/s41421-021-00340-8.

In the absence of virus-targeting small-molecule drugs approved for the treatment and prevention of COVID-19, broadening the repertoire of potent SARS-CoV-2-neutralizing antibodies represents an important area of research in response to the ongoing pandemic. Systematic analysis of such antibodies...

Cite
Gorchakov AA, Kulemzin SV, Guselnikov SV, et al. Isolation of a panel of ultra-potent human antibodies neutralizing SARS-CoV-2 and viral variants of concern. Cell Discov. 2021;7(1):96doi: 10.1038/s41421-021-00340-8.
Gorchakov, A. A., Kulemzin, S. V., Guselnikov, S. V., Baranov, K. O., Belovezhets, T. N., Mechetina, L. V., Volkova, O. Y., Najakshin, A. M., Chikaev, N. A., Chikaev, A. N., Solodkov, P. P., Larichev, V. F., Gulyaeva, M. A., Markhaev, A. G., Kononova, Y. V., Alekseyev, A. Y., Shestopalov, A. M., Yusubalieva, G. M., Klypa, T. V., Ivanov, A. V., Valuev-Elliston, V. T., Baklaushev, V. P., & Taranin, A. V. (2021). Isolation of a panel of ultra-potent human antibodies neutralizing SARS-CoV-2 and viral variants of concern. Cell discovery, 7(1), 96. https://doi.org/10.1038/s41421-021-00340-8
Gorchakov, Andrey A, et al. "Isolation of a panel of ultra-potent human antibodies neutralizing SARS-CoV-2 and viral variants of concern." Cell discovery vol. 7,1 (2021): 96. doi: https://doi.org/10.1038/s41421-021-00340-8
Gorchakov AA, Kulemzin SV, Guselnikov SV, Baranov KO, Belovezhets TN, Mechetina LV, Volkova OY, Najakshin AM, Chikaev NA, Chikaev AN, Solodkov PP, Larichev VF, Gulyaeva MA, Markhaev AG, Kononova YV, Alekseyev AY, Shestopalov AM, Yusubalieva GM, Klypa TV, Ivanov AV, Valuev-Elliston VT, Baklaushev VP, Taranin AV. Isolation of a panel of ultra-potent human antibodies neutralizing SARS-CoV-2 and viral variants of concern. Cell Discov. 2021 Oct 19;7(1):96. doi: 10.1038/s41421-021-00340-8. PMID: 34667147; PMCID: PMC8526700.
Copy Download .nbib Format: NLM
Optimization of Whole Tumor Cell Vaccines by Interaction with Phagocytic Receptors.

Vaccines

Korbelik M.
PMID: 34452029
Vaccines (Basel). 2021 Aug 14;9(8). doi: 10.3390/vaccines9080904.

The principal event in the function of whole-cell cancer vaccines is the ingestion of vaccine-delivered tumor antigen-containing material, which is performed by the patient's antigen-presenting cells (APCs) through the employment of their phagocytic receptors. The goal of the present...

Cite
Korbelik M. Optimization of Whole Tumor Cell Vaccines by Interaction with Phagocytic Receptors. Vaccines (Basel). 2021;9(8)doi: 10.3390/vaccines9080904.
Korbelik, M. (2021). Optimization of Whole Tumor Cell Vaccines by Interaction with Phagocytic Receptors. Vaccines, 9(8), . https://doi.org/10.3390/vaccines9080904
Korbelik, Mladen. "Optimization of Whole Tumor Cell Vaccines by Interaction with Phagocytic Receptors." Vaccines vol. 9,8 (2021). doi: https://doi.org/10.3390/vaccines9080904
Korbelik M. Optimization of Whole Tumor Cell Vaccines by Interaction with Phagocytic Receptors. Vaccines (Basel). 2021 Aug 14;9(8). doi: 10.3390/vaccines9080904. PMID: 34452029; PMCID: PMC8402491.
Copy Download .nbib Format: NLM
Detection of antibodies neutralizing historical and emerging SARS-CoV-2 strains using a thermodynamically coupled de novo biosensor system.

bioRxiv : the preprint server for biology

Zhang JZ, Yeh HW, Walls AC, Wicky BIM, Sprouse K, VanBlargan LA, Treger R, Quijano-Rubio A, Pham MN, Kraft JC, Haydon IC, Yang W, DeWitt M, Chow C, Carter L, Wener MH, Stewart L, Veesler D, Diamond MS, Baker D.
PMID: 34189528
bioRxiv. 2021 Jun 22; doi: 10.1101/2021.06.22.449355.

With global vaccination efforts against SARS-CoV-2 underway, there is a need for rapid quantification methods for neutralizing antibodies elicited by vaccination and characterization of their strain dependence. Here, we describe a designed protein biosensor that enables sensitive and rapid...

Cite
Zhang JZ, Yeh HW, Walls AC, et al. Detection of antibodies neutralizing historical and emerging SARS-CoV-2 strains using a thermodynamically coupled de novo biosensor system. bioRxiv. 2021;doi: 10.1101/2021.06.22.449355.
Zhang, J. Z., Yeh, H. W., Walls, A. C., Wicky, B. I. M., Sprouse, K., VanBlargan, L. A., Treger, R., Quijano-Rubio, A., Pham, M. N., Kraft, J. C., Haydon, I. C., Yang, W., DeWitt, M., Chow, C., Carter, L., Wener, M. H., Stewart, L., Veesler, D., Diamond, M. S., & Baker, D. (2021). Detection of antibodies neutralizing historical and emerging SARS-CoV-2 strains using a thermodynamically coupled de novo biosensor system. bioRxiv : the preprint server for biology, . https://doi.org/10.1101/2021.06.22.449355
Zhang, Jason Z, et al. "Detection of antibodies neutralizing historical and emerging SARS-CoV-2 strains using a thermodynamically coupled de novo biosensor system." bioRxiv : the preprint server for biology vol. (2021). doi: https://doi.org/10.1101/2021.06.22.449355
Zhang JZ, Yeh HW, Walls AC, Wicky BIM, Sprouse K, VanBlargan LA, Treger R, Quijano-Rubio A, Pham MN, Kraft JC, Haydon IC, Yang W, DeWitt M, Chow C, Carter L, Wener MH, Stewart L, Veesler D, Diamond MS, Baker D. Detection of antibodies neutralizing historical and emerging SARS-CoV-2 strains using a thermodynamically coupled de novo biosensor system. bioRxiv. 2021 Jun 22; doi: 10.1101/2021.06.22.449355. PMID: 34189528; PMCID: PMC8240681.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 43 entries